Page 2 - Protein Expression News Today

A new research paper was published in Oncotarget's Volume 14 on December 20, 2023, entitled, "The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies."

Researchers have come one step closer to answering why, in some patients, a type of lymphoma changes from indolent to aggressive, and in particular they are closer to identifying which patients are at high risk of this change happening.

/PRNewswire/ -- Singleron Biotechnologies, a company at the forefront of developing and commercializing innovative single cell multi-omic analysis solutions...

Changes in a person's environment can have long-term, significant effects on the brain, whether it's the inhalation of wildfire smoke or the experience of childhood trauma.

This article delves into the transformative role of membrane proteins in drug development. Discover how Sino Biological's advanced platforms help overcome expression challenges and unlock their potential.

Therapeutic potential of CDR404, as a first-of-its-kind precision immunotherapy for HLA-A*02:01+ patients with MAGE-A4+ squamous non-small cell lung carcinoma (SQ-NSCLC) Development of a Quantitative Systems Pharmacology (QSP) model to facilitate discovery of safe and efficacious doses for upcoming Phase 1 trial ZÜRICH, Switzerland, Nov. 03, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc., in the run-up to initiation of its first Phase 1 clinical trial, presented two posters for CDR404, a first-of-i...

Operator: Thank you for standing by. My name is Aaron, and I will be your conference operator for today.

Researchers have developed EVScape, a predictive tool that identifies which SARS-CoV-2 strains are most likely to evade host immunity. Utilizing a deep generative model and structural information, the tool offers early warning about viral variants, aiding in the timely development of effective vaccines and treatments.

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies today provided an update that its previously announced agreement to divest the Company’s late-stage ophthalmic assets to Laboratoires Théa S.A.S. (Théa) has been terminated. The completion of the transaction was conditional on Théa entering into employment agreements with a ...

PhenomeX Inc., a functional cell biology company, is pleased to announce that GSK will present data on the SpotLight™ Human Lambda reagent for the Beacon® platform at the 16th annual Conference on Protein Expression in Animal Cells, which is being held in Sitges, Spain from September 24-28, 2023.